Class notes
Pharmacology College Notes
- Course
- Institution
This document contains all information from the knowledge clips. Pictures are included with accompanying explanations.
[Show more]
2 reviews
By: ruben1437 • 5 months ago
By: ismayvdo • 1 year ago
Seller
Follow
clairesnel2
Reviews received
Content preview
FARMACOLOGYClaire Snel
GEZONDHEID EN LEVEN
VRIJE UNIVERSITEIT VAN AMSTERDAM
JAAR 2
,Inhoudsopgave
Introduction to pharmacology .......................................................................................................................... 3
Part 1: Pharmacology defined ............................................................................................................................ 3
Part 2: Effects of drugs and drug discovery ........................................................................................................ 3
Pharmacodynamics .......................................................................................................................................... 6
Part 1: Introduction pharmacodynamics ............................................................................................................ 6
Part 2: Molecular theory of drug action ............................................................................................................. 7
Part 3: Molecular drug action: agonists ............................................................................................................. 9
Part 4: Molecular drug action: antagonists and inverse agonists .................................................................... 10
Autonomic nervous system pharmacology ..................................................................................................... 12
Part 1: Introduction to the ANS (design and function)...................................................................................... 12
Part 2: Neurotransmission in the ANS .............................................................................................................. 14
Part 3: Cholinergic neurotransmission in the ANS ............................................................................................ 16
Part 4: Pharmacological control of cholinergic neurotransmission .................................................................. 18
Part 5: Indirect acting (anti)cholinergic drugs and neuromuscular blockers .................................................... 20
Part 6: Adrenergic neurotransmission in the ANS ............................................................................................ 22
Part 7: Pharmacological control of NA neurotransmission .............................................................................. 24
Part 8: Major neurotransmitter systems of the central nervous system .......................................................... 26
Pharmacokinetics ........................................................................................................................................... 29
Part 1: Introduction pharmacokinetics ............................................................................................................. 29
Part 2: Absorption: the role of diffusion ........................................................................................................... 30
Part 3: Absorption: the role of lipid solubility and first-pass effect ................................................................... 31
Part 4: Distribution and excretion ..................................................................................................................... 33
Part 5: Metabolism of drugs ............................................................................................................................. 36
Part 6: Drug distribution and elimination kinetics ............................................................................................ 39
Part 7: Principles of dosing ............................................................................................................................... 42
Part 8: Drug toxicity .......................................................................................................................................... 45
Part 9: Variability in reactions to drugs and population pharmacology ........................................................... 46
Variation in Pharmacokinetics/ Pharmacodynamics ....................................................................................... 49
Part 1: Variation in PK/ PD and variation in PK in children ............................................................................... 49
Part 2: Variation in PK/ PD in elderly, pregnancy and polypharmacy ............................................................... 51
Clinical pharmacological research................................................................................................................... 54
Part 1: Introduction to clinical pharmacological research ................................................................................ 54
Part 2: The phases of CPR and RCT ................................................................................................................... 55
Ethics and drug research in humans ............................................................................................................... 57
Part 1: Defining the field and historical background ........................................................................................ 57
1
, Part 2: Modern practice and moral dilemma’s ................................................................................................. 59
Pharmacotherapy ........................................................................................................................................... 60
2
,Introduction to pharmacology
Part 1: Pharmacology defined
- Pharmacology = explanation of action of pharmaceuticals (= biologically active substances,
including toxins) in the human (or animal) body
- Medicine = pharmaceutical applied for therapy
- Pharmacodynamics (PD) = what does the drug do with the body
- Pharmacokinetics (PK) = what does the body do with the drug
- Pharmacotherapy = applied pharmacology
o Use of knowledge and insight gained from pharmacology for the treatment of diseased
humans in a responsible, effective and safe manner
What is pharmacology
➢ Pharmacology is the study of what drugs do and how they do it
➢ A drug is a chemical that is usually used to treat disease
➢ Drugs are intended to have a selective action, but this ideals is seldom achieved
➢ There is always a risk of adverse effects as well as benefit connected with the use of any drug
> they have to be rated against each other
Pharmacological basis of pharmacotherapy
• In blue: the therapeutic window
o = the concentration of the drug in between the minimum
effective concentration and minimum toxic concentration
o Concentration with acceptable level of benefits versus risk
o The smaller the therapeutic window, the more difficult to
treat patients with a medicine
Part 2: Effects of drugs and drug discovery
- Primary effect = effects for which the compound is administered
- Side effect = adverse/ unwanted effect
o The distinction between the primary effect and side effect is determined by the aim for
which the medicine is administered (e.g. acetylsalicylic acid (aspirine) as a pain killer
(=analgetic) or against blood clotting (= anti-coagulant)
▪ In this case the main side effect is the anti-coagulant effect of aspirine
▪ Nowadays anti-coagulant is the primary effect
>> to conclude, whether it is a primary or side effect depends on what the aim is
for which the drug is used in a moment of time
- Placebo = a preparation without any pharmacologically active substance
- Nocebo = a placebo with unwanted effects (= side effects)
- Placebo effect = a placebo with a (therapeutic) effect
o The strength of this effect is determined to a large extent to the expectations of the
patient
o The contribution of the placebo effect to the overall effects of a drug is investigated in
randomized placebo-controlled clinical trials (RCT)
3
,Sequence of phases in drug discovery and development
➢ The development of drugs is distinguished in two main phases (preclinical phases)
1. Drug discovery
a. Discovery chemistry – synthesizing of the new compounds
b. Discovery biology – to find out whether a large group of synthesized compounds
of a category indeed interact with the target to which they are intended to bind
c. ADME – A (absorption), D (distribution), M (metabolism), E (excretion) >> looking
in vitro whether metabolites are formed
d. Toxicology screening
▪ Information of these activities is fed into lead optimalization and preclinical
development
• Because when started with a library of compounds, eventually that
can only lead to introduction of one optimized compound which can
be introduced
• So, we have to find out as early as possible what is the most likely
small number/ 1 compound to be accepted after performing clinical
trials
▪ Introduce animal models of disease you are interested in
o Pharmacokinetics is extended, looking into more detail of the ADME characteristics of
the drug
o Toxicology screening is extended during lead optimalization and further preclinical
development phases
o Before drugs can be evaluated in humans (phase 1) a proper evaluation must be made
of all the data gathered during the preclinical drug discovery and drug development
2. Drug development
a. Phase 1, 2, 3
Includes:
o Further investigation of the ADME in
humans (both healthy and diseased
humans)
o Medical effects are on a large scale
evaluated during phase 3 (= the phase
prior to a possible registration of the
drug)
Life cycle of drug approval and regulation of use
- Drug discovery: 2-5 years
- Drug development 5-9 years
- FDA (Food and Drug Administration)
approval > has to approve that the drug
can enter the market
o In Europe: EMA (European
Medicines Agency)
- Post-approval regulation = drug is used
in large numbers of patients under the
actual circumstances
4
, College aantekeningen Q&A1
- The four levels of drug action and drug classification > het is lastiger dan het lijkt, we denken
vaak vanuit moleculair niveau (receptoren) iets op te lossen op systemisch niveau, maar zitten
veel stappen tussen
- Levodopa is voorbeeld van een prodrug
- Efficacy = effectiviteit (hoe goed is je stof in staat om een biologisch effect te veroorzaken), dat
is bij een antogonist 0 want er gebeurt niets, daarom geef je die ook
- Efficacy bij agonist is er wel
- S-curve is logaritmische schaal
- Partiele agonist haalt niet de 100%
- Mate van bezetting geeft mate van respons weer = receptortheorie
- Potency = hoogste potency, diegene waarvan je het minste nodig hebt om hetzelfde biologische
effect te bereiken
- Partiele agonisten hebben altijd een lagere efficacy dan volle agonisten
- Niet competitief = Allosterische activators en inhibitors > moduleren de receptor, binden op
een andere plek en beienvloeden zo of de receptor gebonden kan worden
Vragen:
➢ Hoe noemt men een farmacon dat bij binding aan een receptor de activiteit hiervan niet
verandert?
o Inverse agonist (de activiteit van de receptor (die de receptor zelf heeft) gaat omlaag)
o Antagonist
o Placebo (stof bindt wel maar er gebeurt klinisch niets)
o Vals substraat (bindt wel aan enzym, je geeft hem zodat het enzym zijn eigen substraat
minder aanpakt)
➢ Welke van onderstaande parameters bepaalt de mate van receptorbezetting bij een gegeven
concentratie van een geneesmiddel
o De effectiviteit van de binding van het middel aan de receptor (effectiviteit zegt iets over
het biologische effect)
o De aard van het middel (agonist of antagonist)
o De concentratie van het middel in de omgeving van de receptor (conc bepaalt niet wat de
affiniteit is)
o De affiniteit van het middel voor binding aan de receptor
➢ Uit deze curven (zie iphone) blijkt:
o Farmaca B en C zijn volle agonisten
o Farmaca B en C hebben een verschillende effectiviteit (want beiden kunnen 80% van het
effect halen)
o A en C hebben dezelfde affiniteit (bij welke conc krijg ik de helft van de reactie, A heeft
hogere affiniteit want je hebt veel minder nodig van de stof voor 50% van de reactie)
o A en B hebben dezelfde affiniteit (concentratie bij EC50 is hetzelfde, dus zelfde affiniteit.
Ze hebben wel een verschillende efffectiviteit)
➢ Welk van de onderstaande eigenschappen geldt voor een volle receptor antagonist
o Affiniteit die hoger is dan een partiele antagonist (affiniteit heeft er niets mee te maken,
het gaat om effectiviteit)
o Zwakker therapeutisch effect dan een volle agonist
o Intrinsieke effectiviteit/ activiteit is 0
o Hoger molecuulgewicht dan een partiele antagonist
5
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller clairesnel2. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $10.58. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
55628 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now